Research and Clinical Trials

T2009-002 Clofarabine with Cytarabine for MRD Positive Leukemia
Brief Description  
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.
Who may be Eligible  
Patients must be =1 and = 21 years of age when enrolled onto this study. Diagnosis of relapsed acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL). Must have minimal residual disease (MRD) detected by either multidimensional or conventional flow cytometry greater than 0.1% and less than 5% following any re-induction attempt; (CNS) disease status of 1. Atleast 21 days must have elapsed from prior chemotherapy, and at least 7 days must have elapsed since receiving biological therapy and a shortening fraction > 28% or an ejection fraction > 50%. Other conditions apply please contact research nurse.
Pediatric Cancer
IRB Number  
Principal Investigator  
Oesterheld, Javier

For More Information, Contact  Beatriz  , Perez-Li
Phone:  (704) 446-5285  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204